Iovance Biotherapeutics, Inc.IOVANASDAQ
Loading
Year-over-year operating income growth rate
Latest
22.59%
↑ 420% vs avg
Percentile
P100
Near historical high
Streak
3 qtr
Consecutive growthAccelerating
Average
-7.05%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | 22.59% |
| Q3 2025 | 16.59% |
| Q2 2025 | 6.14% |
| Q1 2025 | -40.02% |
| Q4 2024 | 2.80% |
| Q3 2024 | 12.61% |
| Q2 2024 | 13.43% |
| Q1 2024 | 2.91% |
| Q4 2023 | -2.45% |
| Q3 2023 | -7.52% |
| Q2 2023 | 0.69% |
| Q1 2023 | -3.57% |
| Q4 2022 | -6.61% |
| Q3 2022 | -0.66% |
| Q2 2022 | -8.75% |
| Q1 2022 | 7.79% |
| Q4 2021 | -15.33% |
| Q3 2021 | -5.91% |
| Q2 2021 | -7.75% |
| Q1 2021 | -10.27% |
| Q4 2020 | -16.23% |
| Q3 2020 | 7.33% |
| Q2 2020 | 10.14% |
| Q1 2020 | -8.75% |
| Q4 2019 | -26.16% |
| Q3 2019 | -2.88% |
| Q2 2019 | -25.46% |
| Q1 2019 | -14.43% |
| Q4 2018 | 0.33% |
| Q3 2018 | -11.73% |
| Q2 2018 | -16.75% |
| Q1 2018 | -3.09% |
| Q4 2017 | -16.69% |
| Q3 2017 | 5.25% |
| Q2 2017 | -12.93% |
| Q1 2017 | -31.14% |
| Q4 2016 | 16.10% |
| Q3 2016 | -61.84% |
| Q2 2016 | -67.29% |
| Q1 2016 | 17.33% |